Good Manufacturing Practices (GMP) are requirements that help ensure medicines are consistently made and controlled to meet their intended quality. Their history shows how safety failures and new laws shaped the protections used in pharmaceutical manufacturing today.
This timeline follows key U.S. milestones, including the 1906 and 1938 laws, the 1962 amendments and FDA’s first GMP regulations in 1963. It then traces the distinct contributions of WHO, the EU, PIC/S and ICH.
Table of Contents
Why GMP Was Created: Early Problems in Drug Manufacturing
Before modern drug regulations, manufacturers faced limited and inconsistent requirements for process controls, labeling and product safety. Cases of adulteration and misleading claims exposed these gaps and helped build support for stronger laws.
Contamination and Adulteration
Manufacturers mixed drugs in shared, poorly cleaned vessels. As a result, products often contained unknown impurities, microbes, or foreign particles. Some batches harmed patients even when the active ingredient itself was safe.
Misbranding and Misleading Claims
Companies used bold marketing and weak science. They sold tonics as “cures” without proof. Therefore, patients could not know what they received or whether the product contained dangerous solvents, heavy metals, or narcotics.
Limited Process Controls
Workers followed personal habits instead of written procedures. No one tracked critical parameters such as temperature, mixing times, or filtration steps. Consequently, one batch might work, while the next failed silently.
Variability in drug quality
Because controls were weak, potency varied strongly from batch to batch. Sometimes patients received too little drug and stayed ill. Sometimes they received too much and faced serious side effects. These failures slowly built the case for strict, enforceable manufacturing rules.
Early Foundations of GMP (1900–1940)
The history of Good Manufacturing Practices starts with basic consumer protection laws. Between 1900 and 1940, three milestones shaped the first layer of regulation.
1906: Pure Food and Drugs Act
The Pure Food and Drugs Act of 1906 prohibited interstate commerce in adulterated or misbranded food and drugs. It established an early federal enforcement framework, but it did not require manufacturers to prove a new drug’s safety before marketing.
The Act still had limits. It focused on labeling and obvious adulteration. It did not require pre-market proof of safety. However, it sent a clear message: manufacturers could no longer sell anything they wanted without consequences.
1937: Sulfanilamide Tragedy
In 1937, a company formulated a liquid version of sulfanilamide using diethylene glycol, a toxic solvent. The product killed 107 people, many of them children. At the time, the law did not require safety studies on new drugs. FDA could act only on a technicality: “elixir” implied an alcoholic solution, so the product was seized as misbranded. Had it been labelled a “solution”, no legal charge could have been made. No law required toxicity testing of the new elixir, so the company broke no specific regulation at that time.
This tragedy shocked the public and politicians. It showed that safety could not rely on trust or marketing claims. Instead, regulators needed power to demand testing, documentation, and control over how medicines reached the market.
1938: Federal Food, Drug, and Cosmetic Act
The 1938 Federal Food, Drug, and Cosmetic Act required evidence of a new drug’s safety before marketing and expanded FDA’s authority, including factory inspections. It did not establish the later GMP regulations; it strengthened the legal framework that preceded them.
Birth of Modern GMP Standards (1940–1970)
After World War II, pharmaceutical science advanced quickly. New antibiotics, vaccines, and chronic disease treatments moved from labs into mass production. However, this progress brought fresh risks and complexity.
1950s–1960s: Rise of Mass Manufacturing
During the 1950s and 1960s, companies built large production plants and supplied medicines to global markets. Doses became more potent, processes became more intricate, and supply chains grew longer.
Therefore, small errors in one facility could harm thousands of patients worldwide. Governments saw that traditional inspection approaches no longer worked. They needed structured, preventive rules that covered every step of manufacturing, not only final product testing.
1962: Kefauver–Harris Amendments
The thalidomide crisis strengthened the case for U.S. drug-law reform. The 1962 Kefauver–Harris Amendments required evidence of both safety and effectiveness before a new drug could be marketed and established a statutory basis for current good manufacturing practice requirements.
1963: First FDA GMP Regulations
On 20 June 1963, FDA published the first CGMP regulations for drugs (28 FR 6385). They relied on section 501(a)(2)(B) of the FD&C Act, added by the 1962 Drug Amendments, which deems a drug adulterated if its manufacturing methods, facilities or controls do not conform to current good manufacturing practice.
FDA then issued major revisions in 1971, 1978 and 1995. The September 1978 rule (43 FR 45077) is the source of today’s 21 CFR Part 211, which remains the backbone of FDA Good Manufacturing Practices for finished pharmaceuticals., which still form the U.S. GMP backbone today. From this point, modern GMP moved from guidance to enforceable law with direct impact on approvals, inspections, and enforcement actions.
Global Expansion of GMP Standards
As pharmaceutical trade globalized, individual national systems no longer sufficed. Countries needed shared expectations so they could trust each other’s products and inspections.
WHO GMP (1968, updated 1975)
Recognizing this need, the World Health Organization prepared its first draft text on GMP in 1967, adopted the initial version in 1968, and integrated GMP into its Certification Scheme in 1969. In 1975, WHO adopted revised versions of both the scheme and the GMP text, giving regulators a global reference for manufacturing quality.
WHO GMP guidelines helped many countries build or modernize their own regulations. They also supported safer international trade in medicines, especially in low- and middle-income markets.
EU GMP Introduction
In Europe, the thalidomide crisis sparked harmonized medicines legislation.
Council Directive 65/65/EEC of 26 January 1965 required an authorisation from the competent authority before a proprietary medicinal product could be placed on the market, and it set common principles for drug safety, quality and efficacy.
Council Directive 65/65/EEC required prior authorization before a medicinal product could be placed on the market. The first edition of the European Good Manufacturing Practices Guide appeared in 1989. In 1991, Directives 91/356/EEC and 91/412/EEC established GMP principles for human and veterinary medicines, respectively.
The first edition of the EU Guide to Good Manufacturing Practice appeared in 1989 and already included an annex on the manufacture of sterile medicinal products. In 1991, Commission Directives 91/356/EEC for human medicines and 91/412/EEC for veterinary medicines laid down binding GMP principles. The second edition of the Guide, published in January 1992, implemented those directives and added 12 annexes. In 2005, the Guide was restructured into Part I for medicinal products and Part II for active substances used as starting materials. Today, the GMP principles for human medicines are set out in Commission Directive (EU) 2017/1572, which repealed Directive 2003/94/EC.
Over time, the European Commission consolidated GMP guidance into EudraLex Volume 4, the EU GMP Guidelines for human and veterinary medicines. These guidelines interpret legal principles and include annexes for sterile products, biologicals, and advanced therapies, creating a detailed regional framework.
Increasing Global Harmonization
From the late 20th century onward, harmonization became a central theme in the evolution of GMP. Several initiatives reinforced this trend:
- PIC/S (Pharmaceutical Inspection Convention and Scheme): The Pharmaceutical Inspection Convention (PIC) began in 1970. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) was established in 1995 to extend cooperation among regulatory inspectorates. These are related initiatives with distinct names and dates.
- ICH (International Council for Harmonization): ICH was founded in 1990 as the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It brings regulators and industry together to harmonize technical requirements for medicines.
- ICH Q7 and modern quality guidelines: ICH Q7 is the GMP guide for active pharmaceutical ingredients (APIs); it was adopted in 2000. ICH Q8, Q9 and Q10 address pharmaceutical development, quality risk management and pharmaceutical quality systems, respectively.
Today, regulators keep refining GMP for new technologies such as advanced therapy medicinal products, reflected for example in the EU’s dedicated GMP Part IV in 2017.
How GMP Evolved from Final Testing to Quality Systems
GMP first focused heavily on final product testing. Manufacturers checked finished medicines to confirm identity, strength, purity, and quality. However, testing alone could not detect every hidden process failure. Regulators gradually recognized that quality must be built into each manufacturing stage, not inspected only at the end.
- Written procedures standardized critical activities.
- Equipment qualification reduced process variability.
- In-process controls detected problems earlier.
- Quality risk management improved decision-making.
- CAPA systems prevented repeated deviations.
This change led to modern pharmaceutical quality systems. ICH Q7 strengthened GMP expectations for active pharmaceutical ingredients, while ICH Q8, Q9, and Q10 introduced science-based development, risk management, and lifecycle oversight. Today, GMP connects production, quality assurance, validation, training, change control, data integrity, and continuous improvement.
Key Milestones That Shaped the History of GMP
Over more than a century, three forces have kept reshaping the history of Good Manufacturing Practices: major safety events, technology shifts, and regulatory harmonization.
GMP Milestones Since 2000: From Risk-Based Quality to the New Annex 1
Over the last quarter-century, GMP has moved from separate national rules toward a shared, risk-based quality framework. Several milestones explain how today’s expectations took shape.
2000–2008: ICH quality guidelines. ICH Q7, the GMP guide for active pharmaceutical ingredients, reached Step 4 in November 2000. Q8 on pharmaceutical development followed in November 2005, and Q10 on the pharmaceutical quality system in June 2008. Together with Q9 on quality risk management, these guidelines encourage science- and risk-based approaches to quality.
2012–2013: A compounding disaster leads to new US law. In 2012, a fungal meningitis outbreak linked to contaminated compounded steroid injections sickened 751 people in 20 states, 64 of whom died. In response, Congress passed the Drug Quality and Security Act in 2013, which increased regulatory oversight of facilities that make compounded drugs.
2017: GMP for advanced therapies. On 22 November 2017, the European Commission adopted dedicated GMP guidelines for advanced therapy medicinal products. ATMP manufacturers had to comply with them no later than 22 May 2018.
2022–2023: A new Annex 1 for sterile products. The revised EU GMP Annex 1 was adopted in August 2022 and came into operation on 25 August 2023. Its revision aimed to apply the enhanced process understanding and risk-based tools described in ICH Q9 and Q10, and to reflect advances in technology.
2023: Quality risk management refined. ICH Q9(R1) reached Step 4 on 18 January 2023 and made targeted updates to the guidance on quality risk management principles and tools.
Major Drug Safety Events
- Public tragedies as catalysts: Events like the Sulfanilamide disaster and thalidomide crisis showed that weak production controls can destroy lives and trust.
- Ongoing enforcement cases: Every major GMP failure today—contaminated injectables, data integrity scandals, or sterile breaches—usually leads to new guidance, warning letters, and sometimes updated regulations.
Technology Advancements
- From compounding to continuous manufacturing: Early GMP dealt with simple batch processes. Now, companies use automation, continuous manufacturing, real-time analytics, and digital batch records. Consequently, modern GMP emphasizes data integrity, computerized systems, and lifecycle validation.
- Shift toward risk- and science-based control: Tools-like Quality by Design and Quality Risk Management help teams focus on controls where they matter most. Therefore, GMP no longer stops checklists; it demands deep process understanding.
Regulatory Harmonization
- Converging standards: WHO GMP, EU GMP, FDA cGMP, and ICH guidelines now overlap strongly. Differences remain, but core expectations around quality systems, documentation, validation, and change control look very similar.
- Mutual recognition and global supply chains: Arrangements under PIC/S and mutual recognition agreements reduce duplicate inspections and support smoother supply across borders. At the same time, they raise the bar for compliance because one inspection outcome can affect many markets.
GMP history: key milestones in 40 slides (PDF)
Final Words
The history of Good Manufacturing Practices shows how unsafe products, weak laws, and tragedies pushed society to demand protection. Governments and industry turned those lessons into structured GMP systems that control facilities, equipment, processes, and data so every batch of medicine meets strict safety and quality standards.
Understanding this history helps QA, production and regulatory professionals see GMP as a system for protecting patients and maintaining consistent quality. GMP continues to evolve with new technologies, products and regulatory expectations.
FAQ
The history of GMP starts in 1906 with early US food and drug laws. Then, tragedies like the 1937 sulfanilamide disaster and the thalidomide crisis pushed regulators to act. Over time, FDA, WHO, and the EU created structured GMP rules to control every step of drug manufacturing.
The Drug Amendments of 1962, enacted on 10 October 1962, added section 501(a)(2)(B) to the FD&C Act. Under it, a drug is adulterated if its manufacturing methods, facilities or controls do not conform to current good manufacturing practice. FDA then published the first CGMP regulations for drugs on 20 June 1963 (28 FR 6385).
The key milestones are the 1906 Pure Food and Drugs Act, the 1938 FD&C Act, the 1962 Kefauver–Harris Amendments and FDA’s first CGMP regulations in 1963. Internationally, WHO adopted its first GMP text in 1968, PIC began in 1970, the first EU GMP Guide appeared in 1989, PIC/S followed in 1995 and ICH Q7 was adopted in 2000.
WHO adopted its first GMP text in 1968 and built it into its Certification Scheme in 1969, giving many countries a model for national rules. The EU made GMP binding through Directives 91/356/EEC and 91/412/EEC in 1991 and explains those principles in the EU GMP Guide (EudraLex Volume 4). Holders of an EU manufacturing authorisation must follow these principles.
The “C” stands for “current.” FDA explains that companies must use up-to-date technologies and systems to comply, because controls that were adequate 10 or 20 years ago may fall short today. That is why the US term is CGMP, while the EU, WHO and PIC/S usually use GMP.
References
[1] FDA – Milestones in U.S. Food and Drug Law
[2] FDA – Sulfanilamide Disaster (FDA Consumer, June 1981)
[3] Federal Register 61 FR 20104 (3 May 1996) – CGMP proposed amendments, background
[S4] WHO – Global GMP Standards and Certification Scheme
[S5] European Commission – EudraLex Volume 4
[S6] WHO TRS 986, Annex 2 – GMP for pharmaceutical products: main principles (Introduction)
[S7] EUR-Lex – Council Directive 65/65/EEC of 26 January 1965
[S8] PIC/S – History
Stephanie Männicke
Digital Marketing Specialist at Zamann Pharma Support, brings 8 years of experience in Corporate and Digital Communication. Specializing in Digital Marketing and Content Creation, Stephanie is currently focused on creating strategic content for Pharmuni's networks, especially content on topics such as recruitment, onboarding and employer branding. Outside of work, Stephanie is a mum, a crocheter and a movie fan. An avid reader and in search of expanding her knowledge, Stephanie is always looking for ways to innovate communication in the digital environment and connect people in a genuine way.

Protocol Deviations in Clinical Trials: Build an Audit-Ready Record
Protocol deviations can threaten participant protection and trial reliability. This practical guide explains risk-based classification, documentation, escalation, CAPA, and preventive oversight.

eCTD Publishing Software: The Right Features for Submission Success
Discover how eCTD publishing software organizes regulatory dossiers, validates electronic submissions, manages document lifecycles, and supports FDA and EMA workflows.

Pharmaceutical Analytical Testing Services: Essential Quality Insights
A practical guide to pharmaceutical analytical testing services: assay, impurities, dissolution, stability, microbial testing, validation and outsourced-laboratory oversight.